also demonstrated that miR‐146a was a key negative mediator in colonic inflammation and associated cancer by two interlinked mechanisms as follows: (1) in myeloid cells, miR‐146a could target RIPK2 (a NOD2 signalling intermediate) to decrease myeloid cell‐derived IL‐17‐inducing cytokines and restrict the levels of colonic IL‐17. Here, IL17A is linked to cancer.